A citation-based method for searching scientific literature

Albana Gattelli, Nancy E Hynes, Ignacio E Schor, Sabrina A Vallone. J Mammary Gland Biol Neoplasia 2020
Times Cited: 8







List of co-cited articles
38 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
I Plaza-Menacho, A Morandi, D Robertson, S Pancholi, S Drury, M Dowsett, L-A Martin, C M Isacke. Oncogene 2010
101
62

RET rearrangements are actionable alterations in breast cancer.
Bhavna S Paratala, Jon H Chung, Casey B Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B Schrock, Laurie M Gay, Ellen Lee, Sonia C Dolfi,[...]. Nat Commun 2018
58
50

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C Roloff, Martin Schreiber, Neil Carragher, Kenneth K Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner,[...]. EMBO Mol Med 2013
56
50

Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Philip M Spanheimer, Jung-Min Park, Ryan W Askeland, Mikhail V Kulak, George W Woodfield, James P De Andrade, Anthony R Cyr, Sonia L Sugg, Alexandra Thomas, Ronald J Weigel. Clin Cancer Res 2014
29
50

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Anne Boulay, Madlaina Breuleux, Christine Stephan, Caroline Fux, Cathrin Brisken, Maryse Fiche, Markus Wartmann, Michael Stumm, Heidi A Lane, Nancy E Hynes. Cancer Res 2008
91
50

RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
306
37

Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
Robert Mechera, Savas D Soysal, Salvatore Piscuoglio, Charlotte K Y Ng, Jasmin Zeindler, Edin Mujagic, Silvio Däster, Philippe Glauser, Henry Hoffmann, Ergin Kilic,[...]. BMC Cancer 2019
13
37

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.
P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier,[...]. Leukemia 2012
67
25

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
209
25

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
90
25

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
121
25

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
625
25

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
25

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
582
25

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
86
25

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, Robert C Doebele, Wade T Iams, Michael Oh, Victoria M Raymond, Richard B Lanman, Jonathan W Riess, Thomas E Stinchcombe,[...]. Clin Cancer Res 2019
47
25

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
913
25

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
379
25


RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
360
25

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
148
25

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
101
25


Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
S-H Lee, J-K Lee, M-J Ahn, D-W Kim, J-M Sun, B Keam, T M Kim, D S Heo, J S Ahn, Y-L Choi,[...]. Ann Oncol 2017
141
25


RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Kiyohiro Hamatani, Hidetaka Eguchi, Reiko Ito, Mayumi Mukai, Keiko Takahashi, Masataka Taga, Kazue Imai, John Cologne, Midori Soda, Koji Arihiro,[...]. Cancer Res 2008
113
25


RET fusion as a novel driver of medullary thyroid carcinoma.
Elizabeth G Grubbs, Patrick Kwok-Shing Ng, Jacquelin Bui, Naifa L Busaidy, Ken Chen, Jeffrey E Lee, Xinyan Lu, Hengyu Lu, Funda Meric-Bernstam, Gordon B Mills,[...]. J Clin Endocrinol Metab 2015
51
25

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
F Pietrantonio, F Di Nicolantonio, A B Schrock, J Lee, F Morano, G Fucà, P Nikolinakos, A Drilon, J F Hechtman, J Christiansen,[...]. Ann Oncol 2018
57
25


RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
Jan Willem B de Groot, Thera P Links, John T M Plukker, Cornelis J M Lips, Robert M W Hofstra. Endocr Rev 2006
231
25

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Andrea Morandi, Lesley-Ann Martin, Qiong Gao, Sunil Pancholi, Alan Mackay, David Robertson, Marketa Zvelebil, Mitch Dowsett, Ivan Plaza-Menacho, Clare M Isacke. Cancer Res 2013
68
25

Pathways to Endocrine Therapy Resistance in Breast Cancer.
Md Moquitul Haque, Kartiki V Desai. Front Endocrinol (Lausanne) 2019
63
25

Overcoming Endocrine Resistance in Breast Cancer.
Ariella B Hanker, Dhivya R Sudhan, Carlos L Arteaga. Cancer Cell 2020
163
25

RET in breast cancer: functional and therapeutic implications.
Andrea Morandi, Ivan Plaza-Menacho, Clare M Isacke. Trends Mol Med 2011
67
25

Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.
Albana Gattelli, Martín E García Solá, Tim C Roloff, Robert D Cardiff, Edith C Kordon, Lewis A Chodosh, Nancy E Hynes. Oncogene 2018
8
25

RET in breast cancer: pathogenic implications and mechanisms of drug resistance.
Cristiana Lo Nigro, Marta Rusmini, Isabella Ceccherini. Cancer Drug Resist 2019
4
50

Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.
Zachary E Stine, David M McGaughey, Seneca L Bessling, Shengchao Li, Andrew S McCallion. Hum Mol Genet 2011
27
25

Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Haiyuan Xu, Jinge Shen, Jianxing Xiang, Haiyan Li, Bing Li, Tengfei Zhang, Lu Zhang, Xinru Mao, Hong Jian, Yongqian Shu. Cancer Manag Res 2019
26
12

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J Giles, Barbara J Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K Owonikoko, Vijay Peddareddigari, Suresh S Ramalingam,[...]. Cancer Discov 2016
69
12


The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
Valentina De Falco, Francesca Carlomagno, Hong-Yu Li, Massimo Santoro. Best Pract Res Clin Endocrinol Metab 2017
21
12

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Emiliano Cocco, Jamal Benhamida, Sumit Middha, Ahmet Zehir, Kerry Mullaney, Jinru Shia, Rona Yaeger, Liying Zhang, Donna Wong, Liliana Villafania,[...]. Cancer Res 2019
81
12

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
148
12

RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association.
Kerry M Goodman, Svend Kjær, Fabienne Beuron, Phillip P Knowles, Agata Nawrotek, Emily M Burns, Andrew G Purkiss, Roger George, Massimo Santoro, Edward P Morris,[...]. Cell Rep 2014
41
12

Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Tatsuji Mizukami, Kouya Shiraishi, Yoko Shimada, Hideaki Ogiwara, Koji Tsuta, Hitoshi Ichikawa, Hiromi Sakamoto, Mamoru Kato, Tatsuhiro Shibata, Takashi Nakano,[...]. J Thorac Oncol 2014
42
12

Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Zheming Lu, Yujie Zhang, Dongdong Feng, Jindong Sheng, Wenjun Yang, Baoguo Liu. Oncotarget 2017
29
12


Hirschsprung disease, associated syndromes and genetics: a review.
J Amiel, E Sproat-Emison, M Garcia-Barcelo, F Lantieri, G Burzynski, S Borrego, A Pelet, S Arnold, X Miao, P Griseri,[...]. J Med Genet 2008
575
12

REToma: a cancer subtype with a shared driver oncogene.
Takashi Kohno, Junya Tabata, Takashi Nakaoku. Carcinogenesis 2020
23
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.